ClinConnect ClinConnect Logo
Search / Trial NCT06187415

Harm Reduction Strategies for Gay, Bisexual and Other Men Who Have Sex With Men Engaging in Chemsex

Launched by NATIONAL CHENG KUNG UNIVERSITY · Dec 17, 2023

Trial Information

Current as of June 26, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

The practice of sexualized drug use is historical and has been noted across a diversity of genders and people of various sexual orientations. The term "chemsex" has been used to specifically describe the use of psychoactive substances in sexualized settings among gay, bisexual, and other men who have sex with men (GBMSM), particularly stimulants like methamphetamine and mephedrone, or other drugs like γ-hydroxybutyrate (GHB), γ-butyrolactone (GBL). Chemsex among GBMSM has coincided with the emergence of sexual-networking mobile apps, creating new opportunities for finding new partners with ...

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • individuals need to have a history of drug use (ecstasy, ketamine, crystal methamphetamine, mephedrone, and/or GHB/GBL)in a sexualized context in the previous year
  • can read and understand chinese,
  • willing to communicate with the research team through the mobile messenger app Line.
  • Exclusion criteria:
  • None

About National Cheng Kung University

National Cheng Kung University (NCKU) is a prestigious research institution located in Tainan, Taiwan, renowned for its commitment to advancing medical science and innovation. With a strong emphasis on interdisciplinary collaboration, NCKU conducts cutting-edge clinical trials aimed at improving healthcare outcomes and addressing critical health challenges. The university leverages its extensive academic resources and state-of-the-art facilities to foster high-quality research and development, ensuring that its clinical trials adhere to rigorous ethical standards and regulatory compliance. NCKU's dedication to education, research, and community service positions it as a leading sponsor in the field of clinical research, contributing significantly to the global medical landscape.

Locations

Tainan, , Taiwan

Patients applied

0 patients applied

Trial Officials

Carol Strong, PhD

Principal Investigator

National Cheng Kung University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported